The patent expiration date for AbbVie's Teflaro (ceftaroline fosamil) is a subject of interest for those in the pharmaceutical industry. Teflaro is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) [1].

According to DrugPatentWatch.com, a leading resource for patent expiration dates, Teflaro's patent expiration occurred on August 16, 2019 [1]. This information suggests that generic versions of ceftaroline fosamil could enter the market after this date, assuming there are no additional patents or exclusivity periods that may delay generic entry.

It is important to note that the expiration of a drug's patent does not necessarily mean that generic versions will become available immediately. Other factors, such as the regulatory approval process and potential litigation, can influence the timeline for generic entry [2].

In summary, based on the information from DrugPatentWatch.com, the patent for AbbVie's Teflaro (ceftaroline fosamil) expired on August 16, 2019 [1]. However, the availability of generic versions may depend on additional factors beyond the patent expiration date.

Sources:

[1] DrugPatentWatch.com. (n.d.). Ceftaroline Fosamil (Teflaro). Retrieved from https://www.drugpatentwatch.com/drugs/ceftaroline-fosamil-teflaro

[2] U.S. Food and Drug Administration. (2021, March 1). Generic Drugs: Questions and Answers. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/generic-drugs-questions-and-answers